Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center single arm phase II study of MDX-010 (BMS-734016) monotherapy in patients with previously treated unresectable stage III or IV melanoma

Next Previous
Trial Profile

A multi-center single arm phase II study of MDX-010 (BMS-734016) monotherapy in patients with previously treated unresectable stage III or IV melanoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 01 Jun 2009 Two-year survival data was presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Bristol-Myers Squibb media release.
    • 12 Sep 2008 Updated one-year survival data will be presented at the 33rd Congress of the European Society for Medical Oncology in September.
    • 03 Jun 2008 Results presented at ASCO 2008.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top